Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 52-Week Low - Here's What Happened

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $640.28 and last traded at $638.59, with a volume of 349031 shares. The stock had previously closed at $661.00.

Wall Street Analyst Weigh In

Several research firms recently weighed in on REGN. Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Bernstein Bank decreased their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Robert W. Baird reduced their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a report on Wednesday, February 5th. Finally, Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

The stock has a fifty day simple moving average of $683.88 and a two-hundred day simple moving average of $797.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market cap of $69.68 billion, a price-to-earnings ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $11.86 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in REGN. State Street Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. Capital International Investors raised its position in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after purchasing an additional 155,369 shares in the last quarter. Dodge & Cox grew its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after purchasing an additional 9,381 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.